Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MRX 2843

Next Previous
X
Search
Drug Profile

MRX 2843

Alternative Names: MRX-2843

Latest Information Update: 05 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Emory University; Meryx; National Cancer Institute (USA)
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute biphenotypic leukaemia; Acute myeloid leukaemia; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 07 Sep 2024 Efficacy and adverse event data from a phase Ib trial in Non-small cell cancer presented at the 25th World Conference on Lung Cancer (WCLC-2024)
  • 14 Aug 2024 MRX 2843 is still in phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03510104) (Betta Pharmaceuticals pipeline, August 2024)
  • 21 Jun 2024 MRX 2843 is still in phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04762199)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top